98%
921
2 minutes
20
Both hypophosphatemic osteomalacia and primary hyperparathyroidism (PHPT) can lead to hypophosphatemia, but their simultaneous occurrence in the same patient is exceedingly rare. This article reports a case of a 43-year-old female patient whose primary clinical manifestations included pain in the lumbosacral and scapular regions, restricted mobility, and biochemical findings of decreased serum phosphate levels with normal parathyroid hormone (PTH) levels. The patient's symptoms improved after treatment with active vitamin D supplementation, although neutral phosphate supplements were not administered. Eight years later, the patient's symptoms progressively worsened. Further investigations revealed elevated PTH levels and worsening hypophosphatemia. Neck contrast-enhanced ultrasonography and parathyroid radionuclide imaging both indicated nodules in the right parathyroid gland. Postoperative pathological examination confirmed the diagnosis of parathyroid adenoma. Whole-exome sequencing identified a heterozygous deletion in exon 11 of the PHEX gene, consistent with a diagnosis of X-linked hypophosphatemia (XLH).
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12339324 | PMC |
http://dx.doi.org/10.3389/fendo.2025.1634377 | DOI Listing |
Calcif Tissue Int
September 2025
Department of Endocrinology, Post-Graduate Institute of Medical Education and Research (PGIMER), 001, Nehru Extension Block, Chandigarh, India.
Rare diseases, defined by the 2002 Rare Disease Act, affect fewer than 5 in 10,000 individuals. Rare metabolic bone diseases (MBDs), such as osteogenesis imperfecta, hypophosphatasia, osteopetrosis, and other unclassified disorders, can disrupt bone development and remodeling, posing diagnostic and management challenges. This study analyzed data from the rarembd.
View Article and Find Full Text PDFJ Clin Endocrinol Metab
August 2025
Faculté de Médecine Lyon Est, Université de Lyon, Lyon, France.
Introduction: In X-linked Hypophosphatemia (XLH), phosphate and vitamin D analogs increase the risk of nephrocalcinosis and renal impairment. Kidney function assessment is challenging, as creatinine-based eGFR may overestimate GFR due to reduced muscle mass. Cystatin C may be alternatively used.
View Article and Find Full Text PDFBone
August 2025
Pediatric Orthopedics, Deformity Reconstruction and Foot Surgery, Muenster University Hospital, Muenster, Germany; General Orthopedics and Tumor Orthopedics, Muenster University Hospital, Muenster, Germany.
Purpose: X-linked hypophosphatemia (XLH) is a rare metabolic disorder leading to impaired bone mineralization and rickets. Severely affected patients often develop complex, three-dimensional lower limb deformities, resulting in pain and reduced mobility. Although various surgical approaches have been described, deformity recurrence remains common.
View Article and Find Full Text PDFJBMR Plus
September 2025
Department of Endocrinology, The Centre of Postgraduate Medical Education, 01-813 Warsaw, Poland.
McCune-Albright syndrome (MAS) is a rare mosaic genetic disorder caused by a mutation in the gene and typically presents with a triad of symptoms: fibrous dysplasia of bones, café-au-lait macules, and precocious puberty. The mutation leads to overproduction of fibroblast growth factor-23 (FGF23), which may result in hypophosphatemia. Burosumab, a monoclonal antibody against FGF23, is approved for the treatment X-linked hypophosphatemia and tumor-induced osteomalacia.
View Article and Find Full Text PDFFront Endocrinol (Lausanne)
August 2025
Department of Endocrinology and Metabolism, West China Hospital of Sichuan University, Chengdu, Sichuan, China.
Both hypophosphatemic osteomalacia and primary hyperparathyroidism (PHPT) can lead to hypophosphatemia, but their simultaneous occurrence in the same patient is exceedingly rare. This article reports a case of a 43-year-old female patient whose primary clinical manifestations included pain in the lumbosacral and scapular regions, restricted mobility, and biochemical findings of decreased serum phosphate levels with normal parathyroid hormone (PTH) levels. The patient's symptoms improved after treatment with active vitamin D supplementation, although neutral phosphate supplements were not administered.
View Article and Find Full Text PDF